[1] Zetter BR. On target with tumor blood vessel markers. Nat Biotechnol, 1997, 15(12):1243-1244.
[2] Janssen M. Oyen W J, Massuger L F, et al. Comparison of a monomeric and dimeric radiolabeled RGD-peplide for tumor targeling. Cancer Biother Radiopharm, 2002, 17(6):641-646.
[3] Schraa AJ, Kok R J, Moorlag HE, et al. Targeting of RGD-modified proteins to tumor Vasculature:a pharmacokinetic and cellular distribution study. Int J Cancer, 2002,102(5):469-475.
[4] Pasqualini R, Koivtmen E, Ruoslahti E. A peptide isolated from phage display libraries is a structural and functional mimic of an RGD-binding site on integrins. J Cell Biol, 1995, 130(5):1189-1196.
[5] Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage displaypeptide libraries. Nature, 1996,380(6572):364-366.
[6] Rajotte D, Arap W, Hagedorn M, et al. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest, 1998, 102(2):430-437.
[7] Haubner R, Wester HJ, Weber WA, et al. Noninvasive imaging of αvβ3 integrin expression using 18F-labeled-RGD-containing glycopeptide and positron emission tomography. Cancer Res, 2001, 61(5):1781-1785.
[8] Su Z.F, Liu G, Gupta S, et al. In vitro and in vivo evaluation of a 99mTechnetium-labeled cyclic RGD peptide as a specific marker of alpha(V) beta (3) integrin for tumor imaging. Bioconjug Chem, 2002, 13(3):561-570.
[9] Zitzmann S, Ehemann V, Schwab M. Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res, 2002,62(15):5139-5143.
[10] Achilefu S, Blnch S, Markiewicz MA, et al. Synergistic effects of lightemitting probes and peptides for targeting and monitoring integrin expression. Proc Natl Acal Sci USA, 2005, 102(22):7976-7981.
[11] Ye Yp, Bloch S, Xu B. Design synthesis and evaluation of near infrared florescent mehimeric RGD peptides for targeting tumors. J Med Chem. 2006, 49(7):2268-2275.
[12] 李前伟,王曙光,郑秀海,等.125I-RGD-4CY肿瘤αvβ3受体显像的实验研究.第三军医大学学报,2002,24(11):1340-1342.
[13] 程绍钧,李前伟,李忠俊,等.以血管生成为靶点的肿瘤核素显像及治疗的实验研究.第三军医大学学报,2005,27(2):109-111.
[14] Kok R J, Schraa AJ, Bos EJ, et al. Preparation and functional evaluation of RGD-modified proteins as alpha(v)heta(3) integrin direeted herapeuties. Bioconjug Chore, 2002, 13(1):128-135.
[15] Buerkle MA, Pahernik SA, Sutter A, et al. Inhibition of the alphanu integrins with a cyclic RGD peptide impairs angiogenesis,growth and metastasis of solid turnouts in vivo. Br J Cancer, 2002, 86(5):788-795.
[16] Burkhart DJ, Kalet BT, Coleman MP, et al. Doxorubicin-formaldehyde conjugates targeting αvβ3 integrin. Mol Cancer Ther, 2004, 3(12):1593-1604.
[17] Curnis F, Sacchi A, Cortt A. Improving chemotherapeutic drug penetra-tion in tumors by vascular targeting and barrier alteration. J Clin Invest, 2002, 110(4):475-482.
[18] Curnis F, Gasparri A, Sacchi A, et al. Coupling tumor necrosis factor-alpha with alphaV integriu ligands improves its antineoplastic activity. Cancer Res 2004, 64(2):565-571.
[19] 王芳,蒋建伟,曾慧兰,等.整合素受体介导bcl-2反义核酸联合化疗药物对大肠癌细胞的增殖抑制作用.实用医学杂志,2006,22(7):748-749.
[20] 熊小兵,黄悦,吕万良,等.RGD类似物修饰的阿霉素隐形脂质体的制备及体外细胞结合试验.药学学报,2005,40(12):1085-1090.
[21] 邱峰,陈世知,陈虹,等.新型腺病毒载体的制备及其特性研究.重庆医科大学学报,2006,31(3):330-333.
[22] Dijkgraaff I, Kruijtzer JA, Lin S, et al. Improved targeting of the αvβ3 integrin by muhimerisation of RGD peptides. Eur J Nucl Med Mol Imaging, 2007, 34(2):267-273.
[23] Halahan DE, Qu S, Geng L, et al. Radialion-medialed control of drug delivery. Am Clin Oncol, 2001, 24(5):473-480.